US · RNXT
RenovoRx, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Mountain View, CA 94022
- Website
- renovorx.com
Price · as of 2024-12-31
$0.88
Market cap 32.36M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | $3.15 | ||||
| 2022 | $4.33 | ||||
| 2023 | $1.72 | ||||
| 2024 | $0.96 |
AI valuation
Our deep-learning model estimates RenovoRx, Inc.'s (RNXT) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $0.88
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| RNXT | RenovoRx, Inc. | $0.88 | 32.36M | — | — | — | — | -2.56 | 5.04 | 525.37 | -1.43 | — | 5.04 | 100.00% | -25511.63% | -20497.67% | -1192.69% | 333.89% | -183.93% | 0.06 | — | 4.10 | 3.77 | 0.63 | -2600.00% | — | -1093.00% | -40.45% | -4.78 | 278.10% | 0.00% | 0.00% | 25.24% | -1.43 | -1.72 | 365.46 | -8.52 |
| ANVS | Annovis Bio, Inc. | $2.68 | 52.73M | — | — | — | — | 0.00 | 2.28 | — | -0.40 | 0.00 | 2.28 | 0.00% | — | — | -3159092.37% | 361.97% | -203782.88% | 0.00 | -14.40 | 3.59 | 2.72 | 0.40 | 3215955.00% | — | 5468129.00% | -103292.61% | -5641.50 | 296879.29% | 0.00% | 0.00% | 22.63% | -0.40 | 0.00 | — | -16.26 |
| BCAB | BioAtla, Inc. | $0.25 | 14.5M | — | +725% | — | — | -0.24 | 1.17 | 1.52 | 0.43 | — | 1.17 | 91.59% | -672.21% | -634.33% | -164.30% | 204.59% | -81.10% | 0.06 | — | 3.52 | 3.37 | 0.66 | -4419.00% | — | -3091.00% | -429.27% | -4.95 | 199.04% | 0.00% | 0.00% | 0.00% | 0.43 | 0.44 | -2.86 | -16.32 |
| CALC | CalciMedica, Inc. | $0.52 | 7.44M | — | — | — | — | -1.84 | 1.75 | — | -0.27 | — | 1.75 | 0.00% | — | — | -121.42% | 659.51% | -85.68% | 0.00 | — | 5.34 | 5.07 | 0.33 | -8405.00% | — | -1803.00% | -83.97% | -5.74 | 576.40% | 0.00% | 0.00% | 9.55% | -0.27 | -0.31 | — | -11.56 |
| CELU | Celularity Inc. | $1.23 | 29.59M | +3,881% | -60% | — | — | -0.47 | 3.05 | 0.50 | -2.17 | — | -3.47 | 72.36% | -70.75% | -106.77% | -232.51% | -41.90% | -41.86% | 7.79 | -6.12 | 0.38 | 0.27 | -1.56 | -7600.00% | 13811.00% | -8464.00% | -24.37% | -0.12 | -7.17% | 0.00% | 0.00% | 0.00% | -2.48 | -14.48 | 1.75 | -10.21 |
| ELUT | Elutia Inc. | $1.15 | 49.11M | +1,914% | -3% | — | — | -1.50 | -1.74 | 3.31 | -2.01 | — | -1.48 | 43.93% | -146.26% | -221.33% | 127.15% | 103.81% | -135.63% | -0.53 | -7.46 | 0.69 | 0.54 | -0.25 | -1014.00% | -150.00% | 545.00% | -28.90% | -0.60 | 67.88% | 0.00% | 0.00% | 1.47% | -2.59 | -3.95 | 3.78 | -11.28 |
| LTRN | Lantern Pharma Inc. | $2.82 | 31.54M | — | — | — | — | -1.90 | 1.86 | — | -0.70 | 0.00 | 1.86 | 0.00% | — | — | -66.93% | 1620.51% | -60.04% | 0.01 | — | 5.83 | 5.54 | 0.33 | 13125510.00% | — | 2409.00% | -45.25% | -4.11 | 1300.25% | 0.00% | 0.00% | 0.00% | -0.70 | -0.88 | — | -0.66 |
| PYPD | PolyPid Ltd. | $4.25 | 43.31M | — | — | — | — | -2.08 | 6.47 | — | -1.91 | — | 6.47 | 0.00% | — | — | -366.29% | -2641.59% | -143.79% | 0.25 | -48.13 | 1.97 | 1.67 | 0.11 | -5743.00% | — | -10000.00% | 0.00% | 0.00 | 0.00% | 0.00% | 0.00% | 0.00% | -1.84 | — | — | -19.64 |
| RVPH | Reviva Pharmaceuticals Ho… | $0.21 | 14.64M | — | — | — | — | -1.27 | 46.91 | — | -0.84 | — | 46.91 | 0.00% | — | — | -916.17% | 206.33% | -152.63% | 0.56 | -1665.07 | 1.01 | 0.92 | 0.44 | -4545.00% | — | 1843.00% | -88.00% | -2.30 | 224.72% | 0.00% | 0.00% | 0.00% | -0.82 | -0.75 | — | -19.83 |
| TVRD | Tvardi Therapeutics, Inc. | $3.99 | 37.43M | +2,851% | +48% | — | +64,129% | -0.32 | -4.89 | 3.15 | -0.46 | -0.01 | -4.89 | 88.62% | -781.57% | -992.95% | 212.65% | 134.22% | -200.11% | -9.68 | -6.58 | 11.03 | 10.67 | -0.10 | 241838.00% | -6596.00% | 19450.00% | -276.02% | -15.34 | 149.93% | 0.00% | 0.00% | 0.00% | -0.52 | -0.47 | 4.06 | -26.80 |
About RenovoRx, Inc.
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
- CEO
- Shaun R. Bagai
- Employees
- 10
- Beta
- 1.31
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $0.88) − 1 = — (DCF, example).